Nexalin Technology reported a net loss of $6,998,075 for the nine months ended September 30, 2026, compared to $5,845,635 in the prior year period. While revenues for the third quarter increased year-over-year to $78,301, the company continues to face significant operating expenses and an accumulated deficit of nearly $100 million.
Nexalin Technology Partnership with Inovanexa Medical Technologies S.A.
Nexalin Technology entered into a definitive exclusive distribution agreement with Inovanexa Medical Technologies S.A. (operating as Nexalin LATAM) to commercialize the Nexalin Sync™ neurostimulation device across seven South American countries. The 10-year agreement includes an initial 100-device program, minimum revenue thresholds to maintain exclusivity, and a requirement for the distributor to fund and establish a local manufacturing facility in Brazil after the first 30 devices are purchased.
Nexalin Technology has regained compliance with Nasdaq's $1.00 minimum bid price requirement. However, the company remains under a compliance plan to meet the $2.5 million minimum stockholders' equity requirement by January 4, 2027. Failure to meet this remaining equity threshold will subject the company's common stock to delisting.
Nexalin Technology received a notification from the Nasdaq Hearings Panel granting a conditional extension to regain compliance with listing standards. The company must demonstrate a minimum bid price of $1.00 for 20 consecutive trading sessions by September 28, 2026, and meet the $2.5 million stockholders' equity requirement by January 4, 2027.